This episode delves into key takeaways from recent J.P. Morgan Healthcare Conferences, exploring the trends shaping the healthcare industry. We'll examine the surge in obesity drug development and its impact on deal-making. We will also discuss the renewed optimism for deal making in 2024, particularly for late-stage assets, and the slight reopening of the IPO window. The discussion will also highlight the growing influence of AI in drug discovery and R&D, as well as the progress and remaining challenges in cell and gene therapies. Additionally, we’ll cover the shift in care delivery toward more localized and virtual options, the importance of reducing healthcare costs, and the ongoing concerns about healthcare workforce shortages. Finally, we will consider the renewed interest in PPMs and the continued focus on technology solutions for providers and payors.